Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant Melanoma: Southwest Oncology Group S0508

PURPOSE: In limited institution Phase II studies, thalidomide and temozolomide has yielded response rates (RR) up to 32% for advanced melanoma, leading to the use of this combination as “standard” by some. We conducted a multi-center Phase II trial to better define the clinical efficacy of thalidomi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Clark, Joseph I., Moon, James, Hutchins, Laura F., Sosman, Jeffrey A., Kast, W. Martin, Da Silva, Diane M., Liu, P.Y., Thompson, John A., Flaherty, Lawrence E., Sondak, Vernon K.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2811758/
https://ncbi.nlm.nih.gov/pubmed/19918923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24739
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires